Prothena Plc Net Worth
Prothena Plc Net Worth Breakdown | PRTA |
Prothena Plc Net Worth Analysis
Prothena Plc's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Prothena Plc's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Prothena Plc's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Prothena Plc's net worth analysis. One common approach is to calculate Prothena Plc's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Prothena Plc's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Prothena Plc's net worth. This approach calculates the present value of Prothena Plc's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Prothena Plc's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Prothena Plc's net worth. This involves comparing Prothena Plc's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Prothena Plc's net worth relative to its peers.
Enterprise Value |
|
To determine if Prothena Plc is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Prothena Plc's net worth research are outlined below:
| Prothena plc generated a negative expected return over the last 90 days | |
| Prothena plc has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 91.37 M. Net Loss for the year was (147.03 M) with loss before overhead, payroll, taxes, and interest of (81.66 M). | |
| Prothena plc currently holds about 508.8 M in cash with (133.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.84. | |
| Prothena plc has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe |
Prothena Plc uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Prothena plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Prothena Plc's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Prothena Plc's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Prothena Plc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Prothena plc backward and forwards among themselves. Prothena Plc's institutional investor refers to the entity that pools money to purchase Prothena Plc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 719.3 K | Boxer Capital Llc | 2024-09-30 | 690 K | Rock Springs Capital Management Lp | 2024-09-30 | 625 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 526.7 K | Prosight Management, Lp | 2024-09-30 | 483.5 K | Finepoint Capital Lp | 2024-09-30 | 433.5 K | Goldman Sachs Group Inc | 2024-09-30 | 415.3 K | Federated Hermes Inc | 2024-09-30 | 404.9 K | Northern Trust Corp | 2024-09-30 | 372.7 K | Ecor1 Capital, Llc | 2024-09-30 | 11.6 M | Fmr Inc | 2024-09-30 | 8.1 M |
Follow Prothena Plc's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 741.48 M.Market Cap |
|
Project Prothena Plc's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.26) | (0.25) |
When accessing Prothena Plc's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Prothena Plc's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Prothena Plc's profitability and make more informed investment decisions.
Please note, the presentation of Prothena Plc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prothena Plc's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prothena Plc's management manipulating its earnings.
Evaluate Prothena Plc's management efficiency
Prothena plc has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.229) %, meaning that it created substantial loss on money invested by shareholders. Prothena Plc's management efficiency ratios could be used to measure how well Prothena Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -0.22. The current year's Return On Capital Employed is expected to grow to -0.28. At present, Prothena Plc's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 16.1 M, whereas Total Assets are forecasted to decline to about 414.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.55 | 7.17 | |
| Tangible Book Value Per Share | 10.55 | 7.20 | |
| Enterprise Value Over EBITDA | (6.98) | (7.33) | |
| Price Book Value Ratio | 3.44 | 3.62 | |
| Enterprise Value Multiple | (6.98) | (7.33) | |
| Price Fair Value | 3.44 | 3.62 | |
| Enterprise Value | 1.2 B | 618.2 M |
Understanding the operational decisions made by Prothena Plc management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 2.2449 | Revenue 133.3 M | Quarterly Revenue Growth (0.99) | Revenue Per Share 2.482 | Return On Equity (0.23) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prothena Plc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prothena Plc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prothena Plc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prothena Plc Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 3rd of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Prothena Plc Earnings per Share Projection vs Actual
Prothena Plc Corporate Management
| Hideki MD | Chief Officer | Profile | |
| CPA CPA | Chief Controller | Profile | |
| Jennifer Zibuda | Director Communication | Profile | |
| Brandon Smith | Chief Officer | Profile | |
| Wagner Zago | Chief Scientific Officer | Profile | |
| Carol Karp | Chief Regulatory Officer | Profile | |
| David Ford | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prothena plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share 2.482 | Quarterly Revenue Growth (0.99) | Return On Assets (0.16) | Return On Equity (0.23) |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.